This study is looking at a new treatment called *amlitelimab* for people 12 years and older with moderate-to-severe atopic dermatitis (AD), a skin condition that causes itchy, inflamed skin. The study will compare the drug to a placebo, which is a treatment with no active medicine, to see how well it works and how safe it is. It's a blind study, meaning neither the participants nor the doctors know who gets the real medicine or placebo.

Participants can expect to be involved for up to 44 weeks if they choose not to join a further study, or up to 28 weeks if they do. This includes a screening period and several follow-up visits, totaling up to 10 visits.

• The study lasts up to 44 weeks with 10 visits.
• Participants must have had AD for at least a year and weigh over 25 kg.
• There are specific health conditions that can exclude participation.

This study might be a good fit if other treatments have not worked or are not suitable. Participants need to be willing to attend all visits and follow the study rules.